Webinar Overview
Traditional sampling requires larger sample volumes and satellite rodents for accurate, reproducible results. Through microsampling, researchers can collect and analyze small volumes of biofluid from test subjects while still achieving scientifically sound results. Capillary Plasma Microsampling (CMS) has been used to great effect in support of many preclinical safety programs since its validation at Charles River over 10 years ago.
In addition to offering significant ethical benefits, such as actualizing 4Rs (Reduce, Refine, Replace, and Responsibility), CMS also provides important scientific advantages. Developing a more comprehensive understanding of microsampling can alleviate concerns you may have over the reliability and efficiency of data generation.
During this webinar, we share over a decade’s worth of in vivo data and laboratory learnings of CMS application, as well as look towards the future of preclinical and clinical microsampling. You will learn about:
- The evolution of microsample collection and analysis in the preclinical safety assessment space
- How CMS aligns with international expectations as outlined by the UK National Centre for the 3Rs (Reduce, Refine, Replace) and the FDA Modernization Act 2.0
- Steps taken to overcome barriers linked to routine adoption of CMS, and other frequently asked questions
Webinar Presenters
Michael Grant, MSc
Sr. Research Scientist, Chromatographic Bioanalysis
Charles River
Louise Coleman, BSc
Principal Research Scientist, Study Director, General Toxicology
Charles River
Iain Love, BSc
Director, Chromatographic Bioanalysis & Residues
Charles River